Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-01-14Clinical Trial Update: Proton Radiotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC) [Phase 2]
Phase 2 clinical trial update on proton radiotherapy for non-small cell lung cancer completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-01-11Clinical Trial Update: A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement [Phase 2]
A Phase 2 trial update for LDK378 in non-small cell lung cancer with ROS1 rearrangement is reported; the status is currently unknown.
-
CLINICAL_TRIALS trial_result · 2019-01-11Clinical Trial Update: A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations. [Phase 3]
Phase III randomized study assessing intercalating chemotherapy with gefitinib versus chemotherapy alone as adjuvant treatment in completely…
-
CLINICAL_TRIALS trial_result · 2019-01-11Clinical Trial Update: An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement [Phase 2]
Phase II open-label study evaluating LDK378 in NSCLC patients with ROS1 rearrangement (phase 2).
-
CLINICAL_TRIALS trial_result · 2019-01-10Clinical Trial Update: Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC [Phase 4]
A Phase 4 clinical trial evaluating docetaxel plus carboplatin and anlotinib as first-line therapy for non-small cell lung cancer is ongoing…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-01-10Clinical Trial Update: Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations [Phase 1, Phase 2]
A phase 1/2 clinical trial investigating the combination of Vitamin C with a Tyrosine Kinase Inhibitor in non-small cell lung cancer patient…
-
CLINICAL_TRIALS trial_result · 2019-01-03Clinical Trial Update: To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer [Phase 3]
A Phase 3 clinical trial update evaluating SCT510 for non-small cell lung cancer (non-squamous) is ongoing with unknown status.
-
CLINICAL_TRIALS trial_result · 2019-01-03Clinical Trial Update: Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib [Phase 1, Phase 2]
Phase 1/2 trial assessing the combination of ruxolitinib and erlotinib in EGFR-mutant lung adenocarcinoma with acquired resistance to erloti…
-
CLINICAL_TRIALS trial_result · 2019-01-03Clinical Trial Update: A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors [Phase 1, Phase 2]
Phase 1/2 trial evaluating ibritinib in combination with MEDI4736 in relapsed/refractory solid tumors completed with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-01-03Clinical Trial Update: 18F-FSPG PET/CT for Cancer Patients on Therapy [Phase 2]
Phase 2 clinical trial update on 18F-FSPG PET/CT for cancer patients undergoing therapy; study status completed with results posted.
-
FDA approval · 2018-12-21FDA Approved: ALUNBRIG — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for ALUNBRIG (brigatinib) submitted by Takeda Pharmaceuticals America, Inc.
-
CLINICAL_TRIALS trial_result · 2018-12-19Clinical Trial Update: Autologous Tcm Cells Immunotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC) [Phase 2]
Phase 2 trial update of autologous Tcm cell immunotherapy in patients with non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2018-12-19Clinical Trial Update: Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy (ALTER-L006) [Phase 4]
A Phase 4 clinical trial update evaluating anlotinib in elderly patients with advanced non-squamous non-small cell lung cancer who have not …
-
CLINICAL_TRIALS trial_result · 2018-12-19Clinical Trial Update: Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLC [Phase 2]
Phase 2 trial evaluating anlotinib plus pemetrexed in advanced non-squamous non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2018-12-17Clinical Trial Update: Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation [Phase 4]
Phase 4 trial update evaluating afatinib as second-line therapy for non-small cell lung cancer with EGFR mutation; study completed with resu…
-
CLINICAL_TRIALS trial_result · 2018-12-17Clinical Trial Update: A Prospective, Multi-Center Evaluation of a Powered Vascular Stapler in Video-Assisted Thoracoscopic Lobectomies [NA]
A prospective, multi-center study evaluated the use of a powered vascular stapler during video-assisted thoracoscopic lobectomies for non-sm…
-
CLINICAL_TRIALS trial_result · 2018-12-12Clinical Trial Update: A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer [Phase 3]
Phase 3 study of abemaciclib in previously treated KRAS-mutated non-small cell lung cancer has posted results.
-
CLINICAL_TRIALS trial_result · 2018-12-11Clinical Trial Update: Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR [Phase 2]
Phase 2 clinical trial update evaluating erlotinib in patients with resected, early-stage non-small cell lung cancer harboring EGFR mutation…
-
CLINICAL_TRIALS trial_result · 2018-12-07Clinical Trial Update: Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer [Phase 3]
Phase 3 trial evaluating Abraxane maintenance after Abraxane plus carboplatin in first-line stage IIIB/IV squamous cell non-small cell lung …
-
CLINICAL_TRIALS trial_result · 2018-12-07Clinical Trial Update: Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC [Phase 4]
Trial update for anlotinib plus pemetrexed versus pemetrexed for previously untreated elderly or PS 2 non-squamous NSCLC (Phase 4).
-
FDA approval · 2018-12-06FDA Approved: XALKORI — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for XALKORI (crizotinib) submitted by Pfizer Laboratories Div Pfizer Inc.
-
CLINICAL_TRIALS trial_result · 2018-12-06Clinical Trial Update: Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating erlotinib with paclitaxel and carboplatin in stage III/IV or recurrent non-small cell lung cancer has completed wit…
-
CLINICAL_TRIALS trial_result · 2018-12-06Clinical Trial Update: Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative [Phase 2]
Phase 2 clinical trial evaluating anlotinib plus sintilimab for non-small cell lung cancer in patients with resistance to first-generation E…
-
FDA approval · 2018-11-30FDA Approved: XALKORI — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for XALKORI (crizotinib) filed by Pfizer Laboratories Div Pfizer Inc.
-
CLINICAL_TRIALS trial_result · 2018-11-30Clinical Trial Update: Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer [Phase 1]
Phase 1 trial evaluating mogamulizumab in combination with docetaxel for non-small cell lung cancer; the study has completed and results wer…